Extending the clinical pipeline
Their pipeline of novel antimicrobials include eight so far tested of those classed as urgent...
Read moreBenefitting from refocus on core operations
Randall & Quilter IH (R&Q) is a long-established UK and US insurance business led by an experienced...
Read moreDoing all the right things consistently well
Elektron (EKT) is a specialist niche product OEM and B2B operational service provider, enjoying a...
Read moreMaking headway
Raven Property Group (Raven) is a Guernsey registered property investor. Its invests and develops...
Read moreClinical progress with XF drug platform
Recently, positive results from a blinded, placebo-controlled Phase I dermal irritancy study of...
Read moreUpgrading forecasts again
Disruptive technology is turning the world upside down. Look anywhere from online retailing,...
Read moreSeparating the weed from the chaff
The global political and public climate recently took a major step forward in relaxing attitudes to...
Read more'Strong' start to the year
There is nothing wrong with banking a few profits after a parabolic move, especially when a stock...
Read moreBuy one, and get two for free
Elektron (EKT) is a specialist niche product OEM and B2B operational service provider, enjoying a...
Read moreWell-funded and on track for Phase IIb
Destiny is on target for delivering the clinical plan for its novel antimicrobial candidate XF-73...
Read moreTenacity winning through
Raven Russia is a Guernsey registered property investment company specialising in Russian...
Read moreXF-73 green light for the fast track
Confirmation that lead candidate, topical antimicrobial XF-73 has been granted FDA Fast Track...
Read moreRegister to be first
Get research on the companies that interest you straight to your inbox
